# Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

> **NCT02207062** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 20 (actual)

## Conditions studied

- Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
- Refractory Transformed B-Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02207062
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2023-11-01
- **Final completion:** 2023-11-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207062, "Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02207062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*